Life after CAR T for multiple myeloma
Official title: Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11145971 · Data updated 2026-11-12
This project will follow people with relapsed or refractory multiple myeloma who received CAR T to learn about their symptoms, quality of life, and immune changes after treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $690,260 |
| NIH project number | 5R01CA281756-02 |
| Project ID | NIH-11145971 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with relapsed or refractory multiple myeloma who have received CAR T treatment, particularly those treated at or willing to travel to Moffitt Cancer Center for follow-up and sample collection.
✕Less likely to help
Patients who have never received CAR T or who cannot attend clinic visits or provide blood or bone marrow samples are unlikely to benefit directly from participating.
What this research studies
You'll join a prospective group of real-world patients with relapsed/refractory multiple myeloma who received CAR T at Moffitt Cancer Center. Researchers will collect patient-reported outcomes on symptoms, mood, and social support alongside blood and bone marrow samples over time. They will study inflammation and the bone marrow immune environment together with psychosocial measures to see how immune changes and factors like anxiety relate to recovery and survivorship. The goal is to reflect the experiences of more diverse patients treated outside clinical trials to guide future follow-up care and support after CAR T.
Why it matters
Potential benefit: If successful, this work could help tailor follow-up care and supportive services to improve quality of life and long-term outcomes for CAR T recipients with multiple myeloma.
How similar studies have gone: Clinical CAR T trials have shown strong response rates and improved patient-reported outcomes, but they had strict eligibility and limited diversity, so this real-world cohort is a relatively new approach.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Oswald, Laura B. — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Oswald, Laura B.
Related research
Other NIH-funded projects on the same topics.
-
Survivorship in Multiple Myeloma Patients Treated with CAR T-Cell Therapy
This study looks at real-world experiences and well-being of people with multiple myeloma who received CAR T-cell therapy, focusing on their symptoms, mood, and quality of life.
-
Understanding the experiences of multiple myeloma patients treated with CAR T-cell therapy
This study is looking at how patients with relapsed or hard-to-treat multiple myeloma feel and do after receiving CAR T-cell therapy, aiming to understand their health and emotional well-being to help improve their care.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.